Since their inception, angiotensin-converting enzyme (ACE) inhibitors have been used as
first-line therapy for the treatment of cardiovascular and renal diseases. They restore the …

Hypertension is a leading cause of morbidity and mortality worldwide. Individuals with
hypertension are at an increased risk for stroke, heart disease and kidney failure. Essential …

Excess weight is established as a major risk factor for cardiovascular diseases, particularly
in young individuals. To get a better understanding of the pathophysiology underlying …

Background: The renin–angiotensin system (RAS) is thought to have a role in
carcinogenesis, and RAS inhibition may prevent tumour growth. Methods: We …

Background: The renin-angiotensin system (RAS) is related to the regulation of cell
proliferation, angiogenesis, and tumor progression. Patients and Methods: We …

Background: Accumulating pre-clinical and clinical studies suggested that the renin–
angiotensin system blockers (RASBs) possess anti-carcinogenic properties, and their use is …

Introduction: The aim of this study is to evaluate whether the administration of renin-
angiotensin system (RAS) inhibitors, angiotensin-I converting enzyme inhibitors (ACEIs) or …

The renin–angiotensin system (RAS) and inflammation may play a decisive role in
hypertensive end organ damage (EOD) including left ventricular (LV) hypertrophy and …

Sirt1 is a human homologue of the silent information regulator factor 2 (Sir2) and has an
NAD+-dependent histone deacetylase activity. This protein is reported to have a …

Background Angiotensin 2 is a key biologic peptide in the renin–angiotensin system (RAS)
that regulates blood pressure and renal hemodynamics. The potential role of the RAS in the …